US20120053563A1 - Non-sedating antihistamine injection formulations and methods of use thereof - Google Patents

Non-sedating antihistamine injection formulations and methods of use thereof Download PDF

Info

Publication number
US20120053563A1
US20120053563A1 US13/291,514 US201113291514A US2012053563A1 US 20120053563 A1 US20120053563 A1 US 20120053563A1 US 201113291514 A US201113291514 A US 201113291514A US 2012053563 A1 US2012053563 A1 US 2012053563A1
Authority
US
United States
Prior art keywords
sedating antihistamine
sedating
injection
composition
antihistamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/291,514
Inventor
Jie Du
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/291,514 priority Critical patent/US20120053563A1/en
Publication of US20120053563A1 publication Critical patent/US20120053563A1/en
Priority to US13/940,747 priority patent/US9161902B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • Acute allergic reaction including anaphylaxis is a systemic, immediate hypersensitivity reaction caused by exposure to a specific antigen.
  • the immune system activates immunoglobulin E (IgE), which reacts with effector cells (mast cells and basophils). These cells, in turn, release histamine, serotonin, leukotrienes, and prostaglandins, and induce a range of signs and symptoms, such as facial flushing, urticaria (hives), edema, pruritus, broncho-constriction, cough, cardiac arrhythmias, hypotension, nausea, vomiting, and diarrhea. Cutaneous manifestations are most common, with urticaria and angioedema present in 88% or more of patients experiencing acute allergic reactions.
  • Swelling in the airway is the most life-threatening symptom, commonly causing dyspnea, wheezing, stridor, and upper airway obstruction from severe edema.
  • Cardiovascular symptoms include dizziness, hypotension, and syncope related to third-spacing of intravascular fluid.
  • Common gastrointestinal manifestations include nausea, vomiting, abdominal pains or cramps, and diarrhea.
  • Acute allergic reactions occur in all age groups. Food allergies are more common in the young, whereas more drug reactions occur in adults, possibly due to greater exposure to medications, including narcotics, aspirin/NSAIDs, antibiotics, IV contrast media, anesthesia, muscle relaxants, etc. Although prior exposure is essential for the development of true anaphylaxis, reactions occur even when no documented prior exposure exists. Thus, patients may react to a first exposure to an antibiotic or insect sting. Elderly persons have the greatest risk of mortality from acute allergic reactions due to the presence of preexisting disease.
  • Emergency treatment includes airway protection, alpha-agonists, antihistamines, steroids, and beta agonists.
  • Medications currently used in the treatment of acute allergic reactions include epinephrine, diphenhydramine injection, corticosteroids, albuterol, and glucagon.
  • Epinephrine is the first-line drug to be given to a patient having an acute allergic reaction.
  • An alpha-receptor agonist, epinephrine reverses hypotension. It also has beta-receptor activity, which dilates the airways, increases the force of myocardial contraction, and suppresses histamine and leukotriene release, reducing inflammatory responses.
  • Diphenhydramine injection is the second-line drug to be given to a patient having an acute allergic reaction as an adjunct therapy to epinephrine for the relief of peripheral symptoms such as pruritus, engioedema, hives, erythema, etc.
  • a method of treating anaphylaxis or an acute allergic reaction comprises administering to an individual in need thereof an effective amount of an injectable composition comprising a non-sedating (also termed as 2 nd or 3 rd generation) H1 antihistamine wherein the H1 antihistamine comprises cetirizine, loratadine, levocetirizine, desloratadine, or fexofenadine.
  • a non-sedating also termed as 2 nd or 3 rd generation
  • H1 antihistamine comprises cetirizine, loratadine, levocetirizine, desloratadine, or fexofenadine.
  • the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC 0-INF for the injectable formulation as described above to a logarithmic transformed geometric mean of AUC 0-INF for a reference oral product of the non-sedating H1 antihistamine are 0.80 to 1.25; and/or wherein the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC 0-t for the injectable formulation to a logarithmic transformed geometric mean of AUC 0-t for the reference oral product of the non-sedating H1 antihistamine are 0.80 to 1.25.
  • the injectable formulation of the non-sedating antihistamine as described above has a 90% confidence interval around the difference in the reduction of at least one symptom of anaphylaxis or an acute allergic reaction to a reference injectable product, such as diphenhydramine injection, for the per protocol evaluable population, within about ⁇ 30.00 to about +30.00, wherein the symptom is pruritus severity, pruritus duration, erythema, angioedema, number of urticaria areas, number of erythema areas, and/or wheezing.
  • the injectable formulation of the non-sedating antihistamine as described above is statistically superior (p ⁇ 0.05) to a placebo in the reduction of at least one symptom of anaphylaxis or an acute allergic reaction, wherein the symptom is pruritus severity, pruritus duration, erythema, angioedema, urticaria areas, erythema areas, and/or wheezing.
  • an automatic injector designed to allow a user to self-administer a pre-measured dose of a non-sedating antihistamine composition subcutaneously or intramuscularly, comprises a housing comprising a chamber for the non-sedating antihistamine composition and a dispensing assembly in communication with the chamber, wherein the non-sedating antihistamine composition comprises an non-sedating antihistamine and a pH adjusting agent and has a pH of 3 to 9, wherein the non-sedating antihistamine comprises cetirizine, loratadine, levocetirizine, desloratadine, or fexofenadine.
  • a kit comprises the automatic injector comprising a non-sedating antihistamine composition as described above and a second automatic injector comprising a second housing comprising a second chamber for an epinephrine composition and a second dispensing assembly in communication with the second chamber.
  • Acute allergic reaction including anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Pseudoanaphylaxis does not involve an allergic reaction, but is due to direct mast cell degranulation. Both anaphylaxis and pseudoanaphylaxis result in an anaphylactoid reaction and treatment for both conditions is similar.
  • the term anaphylaxis as used herein refers to both conditions unless otherwise specified. Clinical signs and symptoms of acute allergic reaction are given in Table 1:
  • Non-sedating antihistamines to be used, for example, in the hospital or acute care settings.
  • an antigen interacts with and cross-links surface IgE antibodies on mast cells and basophils.
  • IgE antibodies surface IgE antibodies on mast cells and basophils.
  • histamine receptor sites, histamine-1 (H 1 ), and histamine-2 (H 2 ) have a role in acute allergic reactions/anaphylaxis.
  • H 1 receptors Acting on H 1 receptors, histamine produces pruritus, vasodilation, hypotension, flushing, headache, tachycardia, bronchoconstriction, and increased vascular permeability.
  • Histamine causes increased stomach acid production, nausea, and flushing.
  • Symptoms of acute allergic reactions include pruritus, erythema, angioedema, urticaria, urticaria areas, erythema areas, wheezing, and etc.
  • Exemplary patient populations for study include patients coming to emergency rooms or allergy clinics, patients with food allergies (peanuts, other nuts, sea food, etc), patients with exercise induced allergies, patients allergic to insects stings, patients with poison Ivy induced allergies, etc. Additional patients include those already in the hospital experiencing drug induced allergies to: antibiotics, IV contrast media, anesthesia, aspirin/NSAIDs, opioids, chemotherapy agents, muscle relaxants, latex gloves, blood materials, etc.
  • a clinical endpoint bioequivalence study to compare the efficacy of a non-sedating antihistamine or second or third generation antihistamine injection to diphenhydramine injection is performed.
  • the efficacy of a non-sedating antihistamine or second or third generation antihistamine injection is compared to placebo.
  • Pruritus is a condition involving localized or general itching that is a common and distressing symptom in a variety of diseases, especially in an allergic reaction. Although usually occurring in the skin, pruritus can also occur in non-cutaneous sites such as mucous membranes. Erythema is redness of the skin, caused by congestion of the capillaries in the lower layers of the skin.
  • the primary efficacy end points are the difference between the treatment disclosed herein and the treatment of placebo in the mean change from the baseline of the average of the pruritus severity score and the erythema severity score.
  • the study will be designed to give a 90% power to detect a 0.5 unit mean difference for the primary efficacy endpoint at a two-sided alpha-level of 0.05.
  • duration of pruritus as an efficacy end point that can be measured. Duration of pruritus is categorized as follows: 3 if >6 hours/24 hr, 2 if 1 to 6 hours/24 hr, 1 if less than 1 hour/24 hr, and 0 if no pruritus. The study will be designed to give a 90% power to detect a 0.5 unit mean reduction for the primary efficacy endpoint at a two-sided alpha-level of 0.05.
  • Angioedema is an uncomfortable and disfiguring type of temporary swelling especially in the lips and other parts of the mouth and throat, the eyelids, the genitals, and the hand and feet. Angioedema is life-threatening if swelling in your mouth or throat makes it difficult for you to breathe. Less often the sheer amount of swelling means that so much fluid has moved out of the blood circulation that blood pressure drops dangerously.
  • Wheezing is a high-pitched whistling sound produced by air flowing through narrowed breathing tubes, especially the smaller ones deep in the lung.
  • Exemplary clinical studies include a randomized, double-blind, active and placebo-controlled trial of about 300 patients over the age of 12 with acute allergic syndromes. About 100 patients will be randomly assigned to each of the 3 treatments including a non-sedating antihistamine injection as disclosed herein, a diphenhydramine injection, or a placebo injection, all via intravenous, intramuscular or subcutaneous administration. Patients will be recruited at multiple centers, from emergency departments at urban hospitals and allergy clinics throughout the country. The primary endpoints will be the reduction of pruritus severity score, pruritus duration, erythema, angioedema, wheezing, number of urticaria areas, and/or number of erythema areas, at 2-4 hours after protocol treatment. Symptom scores will be also assessed at baseline.
  • ED real-life emergency department
  • Patients over the age of 12 will be considered for recruitment from the ED if they have the following syndromes after an ingested food or ingested, inhaled, or injected drug, after in contact with latex or bee stings: acute urticaria (score 1 and above), acute angioedema (score 1 and above), wheezing (score 1 and above), and acute pruritic rash (score 1 and above).
  • These manifestations should have been present for no greater than 12 hours from the time of alleged allergen exposure.
  • Pregnant patients will be excluded.
  • recruited patients will be randomly assigned to treatment with either 10 mg of cetirizine injection (the test product group, i.e. product of present disclosure), diphenhydramine 50 mg injection (the comparator or active control group) or placebo injection (placebo control group)
  • Each treatment designation will be blinded based on the randomization code.
  • the physician who is unaware of the treatment content will administer the contents by means of intravenous (or intramuscular, or subcutaneous, depending on protocol requirement) injection to the subject.
  • Supplemental medications such as epinephrine, corticosteroids, bronchodilators, and additional doses of antihistamine may be administered at the discretion of the study physicians as a rescue procedure.
  • Patients may also receive supplemental oxygen and intravenous fluids at the discretion of the study physicians as a rescue procedure.
  • Patients will have heart rate, blood pressure, physical findings, side effects, and symptoms assessed at baseline, 1 hour, 2 hours and 4 hours relative to experimental treatment. Baseline temperatures will be also recorded.
  • Clinical recording will include the presence and extent or severity scores of urticaria and erythema, angioedema, wheezing, pruritus, number of urticaria areas, number of erythema areas, abdominal distention or tenderness, and abdominal hyperactive bowel sounds. Historical features, physical findings (including heart rates, blood pressure, and respiratory rates), and treatments will be recorded on a study-specific data input form. The extent of involvement with urticaria and erythema will be assessed by using a check-off cartoon of body areas (similar to that used to assess burn area extent) printed on the data input sheet. Symptom scores will be assessed at baseline, 1 hour, and 2, or 4 hours by using a preprinted form with none (score 0), mild (score 1), moderate (score 2), and severe (score 3) check-off categories.
  • the primary variables of interest will be resolution or reduction of urticaria, angioedema, erythema, pruritus, wheezing, number of urticaria areas, and number of erythema areas. Changes in heart rates, respiratory rates, blood pressure, and symptoms will also be examined. The final disposition of the patient will be noted (admission, discharge, or leaving against medical advice). The study will be approved by the institutional review board, and informed written consent will be obtained from all patients.
  • Statistical assessment will be using bivariate 2 analysis and analysis of variance or covariance (ANCOVA), multivariate logistic regression. Covariates will be included in some multivariate models. Analyses will be performed by using the SAS software. Certain statistical values are expressed with 90% confidence intervals (CIs).
  • the above clinical trials may be split into two separate studies.
  • One study will be an active controlled study comparing the invention injectable product with diphenhydramine injection.
  • the other will be a placebo controlled study comparing the invention injectable product with a placebo.
  • Prompt treatment with antihistamines is highly recommended to alleviate the symptoms of acute allergic reactions.
  • Antihistamines are helpful in reducing histamine-mediated vasodilation and secondary edema.
  • Commonly used drugs such as diphenhydramine injection provide H 1 blockade.
  • Diphenhydramine reduces vasodilation in small blood vessels in the nose, eyes, and airways and provide some anticholinergic effects toward drying secretions.
  • Diphenhydramine (1 to 2 mg/kg, up to a maximum of 50 mg, given IV or IM) is the drug of choice when treating acute allergic reactions.
  • Concomitant administration of an H 2 agonist such as ranitidine (1 mg/kg IV) or cimetidine (4 mg/kg IV) is also of value to provide antihistaminic effect.
  • the only antihistamine injection existing on the market is diphenhydramine injection, a first generation antihistamine, with known side effects of cardio toxicity (QT prolongation), severe sedation, anti-cholinergic effect, potential of drug/drug interaction, and short acting which requires 3-4 doses a day.
  • Cardio toxicity presents a huge safety concern, and the sedation side effect causes significantly inconvenience and discomfort for patients.
  • the sedating side effect presents a safety concern when patients have to drive home themselves after being discharged from the emergency room.
  • the sedating side effect also interferes with neurological exams for patients who are in need such exams in the hospital. Patients with allergic reactions to opioids are treated with diphenhydramine injections. This causes a dangerous additive effect in sedation.
  • Diphenhydramine's QT prolongation is potentially life threatening and could lead to hospital admission.
  • QT prolongation is worsened by drug/drug interaction.
  • diphenhydramine injection is frequently used as a preventive measure to desensitize antibiotics (antibiotics have a high incidence for drug induced allergic shock).
  • ICUs patients are normally on multiple medications, and the potential drug/drug interaction and liver enzyme P450 inhibition leading to cardiac arrest due to QT prolongation is extremely dangerous.
  • Diphenhydramine injection is commonly used together with blood transfusion to prevent allergic reactions to blood or plasma. Clearly sedation is unwanted. Diphenhydramine injection is often used to treat anesthesia induced allergies in the operating room. It takes longer for patients to awake from the anesthesia when diphenhydramine injection is co-used.
  • the present disclosure includes injectable formulations of second and third generation antihistamines, or non-sedating antihistamines, via intravenous, intramuscular, or subcutaneous administration to provide an immediate onset of action.
  • second and third generation antihistamines are commercially available as oral dosage forms as shown in the following table.
  • Additional non-sedating antihistamines include des-diphenhydramine, epinastine, azelastine, Acrivastine, Ebastine, carbastine, levocarbastine, Mizolastine, and Rupatadine.
  • Parenteral injectable formulations may be in unit dose form in ampoules, small volume parenteral (SVP) vials, large volume parenterals (SVP), pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
  • oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, buffering, emulsifying or suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
  • Parenteral injectable formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably at a pH of from 3 to 9.5), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • excipients such as salts, carbohydrates and buffering agents (preferably at a pH of from 3 to 9.5)
  • a suitable vehicle such as sterile, pyrogen-free water.
  • the injectable compositions contain a solution of one or more non-sedating antihistamines in an aqueous solvent combined with a buffer or pH adjusting agents having a pH of 3 to 9.
  • the composition optionally contains at least one isotonicity agent.
  • a water-insoluble inert gas may be carefully bubbled through the aqueous solvent to remove oxygen from the medium.
  • the compositions contain at least one preservative and/or at least one solubility enhancing agent and/or at least one stabilizing agent.
  • the non-sedating H1 antihistamine is cetirizine or a salt thereof.
  • the quantity of cetirizine or salt thereof in the injection formulation is 1-100 mg per milliliter of liquid, preferably 1.5-50 mg, more preferably 2-25 mg per milliliter of liquid.
  • the non-sedating H1 antihistamines is fexofenadine or a salt thereof.
  • the quantity of fexofenadine or salt thereof in the injection formulation is 1-200 mg per milliliter of liquid, preferably 1.5-180 mg, preferably 2-90 mg, more preferably 2.5-70 mg per milliliter of liquid.
  • the injectable composition optionally comprises at least one H2 antihistamine, specifically ranitidine and cimetidine, more specifically ranitidine.
  • Concomitant administration of an H2 agonist such as ranitidine (1 mg/kg IV) or cimetidine (4 mg/kg IV) may be of value to provide antihistaminic effect.
  • An automatic injector or auto-injector is a device designed to allow a user to self-administer a pre-measured dose of a medicament composition subcutaneously or intramuscularly, usually in an emergency situation.
  • a typical auto-injector has a housing, inside of which is a cartridge.
  • the cartridge has one or several chambers containing medicament compositions or components thereof and is in communication with a dispensing assembly such as needle assembly.
  • the cartridge can hold either a pre-mixed liquid medicament or a solid medicament and a liquid that are mixed prior to injection.
  • the housing carries an actuation assembly with a stored energy source, for example, a compressed spring.
  • Activation of the actuation assembly causes a sequence of movements, whereby the needle extends from the auto-injector into the user so that the medicament compound is then forced through the needle and into the user. After delivery of the dose of medicament into the injection site, the needle remains in an extended position or in a hidden position.
  • the auto-injector is of the type designed to carry plural components of the medicament composition in separate, sealed compartments, structure may be included that forces the components to mix when the actuation assembly is activated.
  • Autoinjectors for antihistamine administration do not exist. Advantages of the use of auto-injectors to dispense non-sedating (second and third generation) antihistamines for the treatment of severe allergic reactions include availability for emergency treatment, precise dosing, portability, readiness for use, rapid intramuscular or subcutaneous administration, administration through clothing and protective wear, and rapid self-administration. The advantages of this invention also include its non-cardiotoxicity (no QT prolongation), and non-sedating. Unlike the current highly sedating diphenhydramine injections, the non-sedating feature of this invention allows patients to be alert enough to drive to the hospital or emergency care facility after they self administer the non-sedating antihistamine injection via an auto injector.
  • a kit comprises the automatic injector comprising a non-sedating antihistamine composition as described above, and a second automatic injector comprising a second housing comprising a second chamber for an epinephrine composition and a second dispensing assembly in communication with the second chamber.
  • an injectable second or third generation antihistamine (non-sedating antihistamine) formulation comprising administering to an individual in need thereof an effective amount of an injectable composition comprising a second or third generation antihistamine (or non-sedating antihistamine).
  • the antihistamine is not diphenhydramine.
  • the non-sedating antihistamine is selected from cetirizine, loratadine, levocetirizine, desloratadine, and fexofenadine, des-diphenhydramine, epinastine, azelastine, Acrivastine, Ebastine, carbastine, levocarbastine, Mizolastine, and Rupatadine.
  • the injectable formulation further comprises at least one H2 receptor antagonist, such as ranitidine or cimetidine.
  • the injectable formulation further comprises epinephrine.
  • the injectable formulation further comprises at least one steroid, such as methylprednisolone or prednisolone.
  • disclosed herein are methods of treating an acute allergic reaction comprising administering to an individual in need thereof an effective amount of an injectable composition comprising a second or third generation antihistamine (or non-sedating antihistamine), wherein the injectable composition is bioequivalent to an oral formulation of the 2 nd or 3 rd generation antihistamine.
  • Non-sedating Dosage range of injectable Antihistamine Oral product formulation Cetirizine 10 mg tablet about 2 mg to about 10 mg 10 mg chewable tablet 10 mg capsule 5 mg tablet 5 mg/5 mL syrup
  • Loratadine 10 mg tablet about 1 mg to about 10 mg 10 mg capsule 5 mg tablet 5 mg chewable tablet 0.5 mg/mL syrup 1 mg/mL suspension 1 mg/mL syrup
  • Fexofenadine 180 mg tablet/capsule about 5 mg to about 60 mg tablet 180 mg 30 mg tablet 30 mg/5 mL suspension
  • Levocetirizine 5 mg tablet about 1 mg to about 5 mg 2.5 mg tablet 2.5 mg/5 mL syrup Desloratadine 5 mg tablet about 1 mg to about 5 mg 2.5 mg/5 mL syrup
  • the term equivalent to an oral product means that the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC 0-INF and/or AUC 0-t for the injectable formulation to a logarithmic transformed geometric mean of AUC 0-INF and/or AUC 0-t for the reference oral product are about 0.80 to about 1.25, specifically 0.80 to 1.25.
  • AUC is the area under the curve of a graph of the measured concentration of an active agent (typically plasma concentration) vs. time, measured from one time point to another time point.
  • AUC 0-t is the area under the curve of plasma concentration versus time from time 0 to time t, the last blood draw time point.
  • the AUC 0- ⁇ or AUC 0-INF is the calculated area under the curve of plasma concentration versus time from time 0 to time infinity by extrapolation.
  • the AUC 0-INF and/or AUC 0-t are given in Table 2.
  • the AUC INF and/or AUC 0-t for the injectable formulation and the reference oral dosage form are given determined in a reference-controlled study.
  • disclosed herein are methods of treating an acute allergic reaction including anaphylaxis comprising administering to an individual in need thereof an effective amount of an injectable composition comprising a second or third generation antihistamine (or non-sedating antihistamine), wherein the injectable composition is therapeutically equivalent to a reference diphenhydramine injectable formulation.
  • the reference diphenydramine injectable formulation is a 50 mg/mL solution, and the dose is about 12.5-150 mg dose.
  • Diphenhydramine injection is commercially available from Pfizer as Benadryl® Injection. Many generic versions of diphenhydramine injections are also available on the market. Therapeutic equivalence can be determined in a reference-controlled study using a diphenydramine injectable formulation as the reference.
  • therapeutically equivalent to a reference diphenydramine injectable formulation means that the test formulation has a 90% confidence interval around the difference in the reduction of at least one symptom of an acute allergic reaction including anaphylaxis of the test drug to the reference drug, for the per protocol evaluable population, within about ⁇ 30.00 to about +30.00.
  • the symptoms of anaphylaxis or an acute allergic reaction are, pruritus severity, pruritus duration, erythema, angioedema and/or wheezing reduction, and urticaria areas or erythema areas.
  • a placebo is an inactive pill, liquid, or powder that has no treatment value.
  • experimental treatments are often compared with placebos to assess the treatment's effectiveness.
  • a placebo-controlled study is a method of investigation of drugs in which an inactive substance (the placebo) is given to one group of participants, while the drug being tested is given to another group. The results obtained in the two groups are then compared to see if the investigational treatment is more effective in treating the condition.
  • therapeutically effective compared to placebo means that the treatment of this invention is statistically superior (p ⁇ 0.05) to a placebo in the reduction of at least one symptom of anaphylaxis or an acute allergic reaction, wherein the symptom is pruritus severity, pruritus duration, erythema, angioedema, urticaria areas, erythema areas, and/or wheezing.
  • the methods described herein optionally further comprise administering a second active agent as well as the second or third generation antihistamine.
  • the second active agent is an H2 receptor antagonist, such as ranitidine or cimetidine.
  • the second active agent is epinephrine.
  • the second active agent comprises at least one steroid, such as methylprednisolone or prednisolone.
  • the methods disclosed herein further comprise administering a second active agent comprising ranitidine, cimetidine, epinephrine, methylprednisolone, prednisolone, or a combination thereof.
  • non-sedating antihistamines represent the 2 nd and/or 3 rd generation antihistamines that are truly non-sedating and that are less-sedating than diphenhydramine.
  • antihistamine can also be expressed as “antagonist of the H1 receptor” or “H1 antihistamine”.
  • the term “Therapeutic equivalence” can also be expressed as “clinical equivalence”, “clinically bioequivalent”, or “clinical endpoint bioequivalence”.
  • Acute allergic reaction means an allergic condition of the immediate type, severe allergies/anaphylaxis, or severe allergic reaction such as allergic reactions to blood or plasma, to food, to medications, or to other allergy inducing materials.

Abstract

Described herein are automatic injectors suitable for administration of a non-sedating antihistamine, and methods of using the automatic injectors. A specific non-sedating antihistamine is cetirizine. The automatic injectors are useful in treating acute urticaria or angioedema associated with an acute allergic reaction including anaphylaxis.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application is a divisional of U.S. patent application Ser. No. 12/704,089, filed Feb. 11, 2010, which is a nonprovisional of U.S. Provisional Application Ser. Nos. 61/248,441 filed Oct. 3, 2009 and 61/222,951 filed Jul. 3, 2009, all which are hereby incorporated by reference in their entirety.
    • BACKGROUND
  • Acute allergic reaction including anaphylaxis, is a systemic, immediate hypersensitivity reaction caused by exposure to a specific antigen. The immune system activates immunoglobulin E (IgE), which reacts with effector cells (mast cells and basophils). These cells, in turn, release histamine, serotonin, leukotrienes, and prostaglandins, and induce a range of signs and symptoms, such as facial flushing, urticaria (hives), edema, pruritus, broncho-constriction, cough, cardiac arrhythmias, hypotension, nausea, vomiting, and diarrhea. Cutaneous manifestations are most common, with urticaria and angioedema present in 88% or more of patients experiencing acute allergic reactions. Swelling in the airway is the most life-threatening symptom, commonly causing dyspnea, wheezing, stridor, and upper airway obstruction from severe edema. Cardiovascular symptoms include dizziness, hypotension, and syncope related to third-spacing of intravascular fluid. Common gastrointestinal manifestations include nausea, vomiting, abdominal pains or cramps, and diarrhea. Although symptoms vary between acute allergy patients, onset generally occurs seconds to minutes after exposure to an antigen and requires prompt treatment.
  • The true incidence of acute allergic reactions including anaphylaxis is unknown, partly because of the lack of a precise definition of the syndrome. Some clinicians reserve the term anaphylaxis for the full-blown syndrome, while others use it to describe milder cases. Fatal anaphylaxis is relatively rare; milder forms occur much more frequently. The frequency of acute allergic reaction is increasing, and this has been attributed to the increased number of potential allergens to which people are exposed, such as increased varieties of food and medications. A recent review concluded that the lifetime prevalence of acute allergic reactions including anaphylaxis is ˜5% of the population with higher prevalence in developed countries than developing countries.
  • Approximately 1 in 5000 exposures to a parenteral dose of a penicillin or cephalosporin antibiotic causes anaphylaxis. More than 100 deaths per year are reported in the United States due to antibiotic induced allergies. Fewer than 100 fatal reactions to Hymenoptera stings are reported each year in the United States but this is considered to be an underestimate. One to 2% of people receiving IV radiocontrast experience some sort of reaction. The majority of these reactions are minor, and fatalities are rare. Low molecular weight contrast causes fewer and less severe reactions. Narcotics also induce acute allergic reactions.
  • Acute allergic reactions occur in all age groups. Food allergies are more common in the young, whereas more drug reactions occur in adults, possibly due to greater exposure to medications, including narcotics, aspirin/NSAIDs, antibiotics, IV contrast media, anesthesia, muscle relaxants, etc. Although prior exposure is essential for the development of true anaphylaxis, reactions occur even when no documented prior exposure exists. Thus, patients may react to a first exposure to an antibiotic or insect sting. Elderly persons have the greatest risk of mortality from acute allergic reactions due to the presence of preexisting disease.
  • Emergency treatment includes airway protection, alpha-agonists, antihistamines, steroids, and beta agonists. Medications currently used in the treatment of acute allergic reactions include epinephrine, diphenhydramine injection, corticosteroids, albuterol, and glucagon. Epinephrine is the first-line drug to be given to a patient having an acute allergic reaction. An alpha-receptor agonist, epinephrine reverses hypotension. It also has beta-receptor activity, which dilates the airways, increases the force of myocardial contraction, and suppresses histamine and leukotriene release, reducing inflammatory responses. Diphenhydramine injection is the second-line drug to be given to a patient having an acute allergic reaction as an adjunct therapy to epinephrine for the relief of peripheral symptoms such as pruritus, engioedema, hives, erythema, etc.
  • What is needed are additional treatments for severe allergic reactions including anaphylaxis.
    • SUMMARY
  • In one aspect, a method of treating anaphylaxis or an acute allergic reaction comprises administering to an individual in need thereof an effective amount of an injectable composition comprising a non-sedating (also termed as 2nd or 3rd generation) H1 antihistamine wherein the H1 antihistamine comprises cetirizine, loratadine, levocetirizine, desloratadine, or fexofenadine.
  • In another aspect, the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC0-INF for the injectable formulation as described above to a logarithmic transformed geometric mean of AUC0-INF for a reference oral product of the non-sedating H1 antihistamine are 0.80 to 1.25; and/or wherein the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC0-t for the injectable formulation to a logarithmic transformed geometric mean of AUC0-t for the reference oral product of the non-sedating H1 antihistamine are 0.80 to 1.25.
  • In yet another aspect, the injectable formulation of the non-sedating antihistamine as described above has a 90% confidence interval around the difference in the reduction of at least one symptom of anaphylaxis or an acute allergic reaction to a reference injectable product, such as diphenhydramine injection, for the per protocol evaluable population, within about −30.00 to about +30.00, wherein the symptom is pruritus severity, pruritus duration, erythema, angioedema, number of urticaria areas, number of erythema areas, and/or wheezing.
  • In another aspect, the injectable formulation of the non-sedating antihistamine as described above is statistically superior (p<0.05) to a placebo in the reduction of at least one symptom of anaphylaxis or an acute allergic reaction, wherein the symptom is pruritus severity, pruritus duration, erythema, angioedema, urticaria areas, erythema areas, and/or wheezing.
  • In another aspect, an automatic injector designed to allow a user to self-administer a pre-measured dose of a non-sedating antihistamine composition subcutaneously or intramuscularly, comprises a housing comprising a chamber for the non-sedating antihistamine composition and a dispensing assembly in communication with the chamber, wherein the non-sedating antihistamine composition comprises an non-sedating antihistamine and a pH adjusting agent and has a pH of 3 to 9, wherein the non-sedating antihistamine comprises cetirizine, loratadine, levocetirizine, desloratadine, or fexofenadine.
  • In yet another aspect, a kit comprises the automatic injector comprising a non-sedating antihistamine composition as described above and a second automatic injector comprising a second housing comprising a second chamber for an epinephrine composition and a second dispensing assembly in communication with the second chamber.
    • DETAILED DESCRIPTION
  • Acute allergic reaction including anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Pseudoanaphylaxis does not involve an allergic reaction, but is due to direct mast cell degranulation. Both anaphylaxis and pseudoanaphylaxis result in an anaphylactoid reaction and treatment for both conditions is similar. The term anaphylaxis as used herein refers to both conditions unless otherwise specified. Clinical signs and symptoms of acute allergic reaction are given in Table 1:
  • TABLE 1
    Clinical signs and symptoms of acute allergic reactions including
    anaphylaxis
    Cutaneous/subcutaneous/mucosal tissue
      Flushing, pruritus, hives (urticaria), angioedema, morbilliform rash,
      pilor erection
      Pruritus of lips, tongue, and palate; edema of lips, tongue, and uvula
      Periorbital pruritus, erythema and edema, conjunctival erythema,
      tearing
    Respiratory
      Laryngeal: pruritus and tightness in the throat, dysphagia, dysphonia
      and hoarseness, dry staccato cough, stridor, sensation of pruritus in
      the external auditory canals
      Lung: shortness of breath, dyspnea, chest tightness, deep cough and
      wheezing/bronchospasm (decreased peak expiratory flow)
      Nose: pruritus, congestion, rhinorrhea, sneezing
    Cardiovascular
      Hypotension
      Feeling of faintness (near-syncope), syncope, altered mental status
      Chest pain, dysrhythmia
    Gastrointestinal
      Nausea, crampy abdominal pain, vomiting (stringy mucus), diarrhea
    Other
    Uterine contractions in women, and aura of doom
  • Disclosed herein are injection formulations of non-sedating antihistamines to be used, for example, in the hospital or acute care settings. In allergic reactions, an antigen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast-cell-antibody-antigen complex is formed, a complicated series of events occurs that eventually leads to mast cell degranulation and the release of histamine and other chemical mediators from the mast cell or basophil. After its release, histamine can react with local or widespread tissues through histamine receptors. Histamine receptor sites, histamine-1 (H1), and histamine-2 (H2) have a role in acute allergic reactions/anaphylaxis. Acting on H1 receptors, histamine produces pruritus, vasodilation, hypotension, flushing, headache, tachycardia, bronchoconstriction, and increased vascular permeability. Targeting H2-receptor sites, histamine causes increased stomach acid production, nausea, and flushing.
  • Symptoms of acute allergic reactions include pruritus, erythema, angioedema, urticaria, urticaria areas, erythema areas, wheezing, and etc. Exemplary patient populations for study include patients coming to emergency rooms or allergy clinics, patients with food allergies (peanuts, other nuts, sea food, etc), patients with exercise induced allergies, patients allergic to insects stings, patients with poison Ivy induced allergies, etc. Additional patients include those already in the hospital experiencing drug induced allergies to: antibiotics, IV contrast media, anesthesia, aspirin/NSAIDs, opioids, chemotherapy agents, muscle relaxants, latex gloves, blood materials, etc.
  • In one aspect, a clinical endpoint bioequivalence study to compare the efficacy of a non-sedating antihistamine or second or third generation antihistamine injection to diphenhydramine injection is performed. In another embodiment, the efficacy of a non-sedating antihistamine or second or third generation antihistamine injection is compared to placebo.
  • Pruritus is a condition involving localized or general itching that is a common and distressing symptom in a variety of diseases, especially in an allergic reaction. Although usually occurring in the skin, pruritus can also occur in non-cutaneous sites such as mucous membranes. Erythema is redness of the skin, caused by congestion of the capillaries in the lower layers of the skin. The primary efficacy endpoints included the pruritus severity score and the erythema severity score (scored on a 0=absent, 1=mild, 2=moderate, to 3=severe scale, at 0.5 increments), and the reduction of the scores following treatment. For clinical trials, patients with “score 1-3” (mild to severe) will be recruited.
  • The primary efficacy end points are the difference between the treatment disclosed herein and the treatment of placebo in the mean change from the baseline of the average of the pruritus severity score and the erythema severity score. The study will be designed to give a 90% power to detect a 0.5 unit mean difference for the primary efficacy endpoint at a two-sided alpha-level of 0.05.
  • In addition, the duration of pruritus as an efficacy end point that can be measured. Duration of pruritus is categorized as follows: 3 if >6 hours/24 hr, 2 if 1 to 6 hours/24 hr, 1 if less than 1 hour/24 hr, and 0 if no pruritus. The study will be designed to give a 90% power to detect a 0.5 unit mean reduction for the primary efficacy endpoint at a two-sided alpha-level of 0.05.
  • Angioedema is an uncomfortable and disfiguring type of temporary swelling especially in the lips and other parts of the mouth and throat, the eyelids, the genitals, and the hand and feet. Angioedema is life-threatening if swelling in your mouth or throat makes it difficult for you to breathe. Less often the sheer amount of swelling means that so much fluid has moved out of the blood circulation that blood pressure drops dangerously. The primary efficacy endpoints for angioedema include the angioedema severity score (scored on a 0=absent, 1=mild, 2=moderate, to 3=severe scale, at 0.5 increments), and the reduction of the score following treatment.
  • Wheezing is a high-pitched whistling sound produced by air flowing through narrowed breathing tubes, especially the smaller ones deep in the lung. The primary efficacy endpoints include the wheezing severity score (scored on a 0=absent, 1=mild, 2=moderate, to 3=severe scale, at 0.5 increments), and the reduction of the score following treatment.
  • Exemplary clinical studies include a randomized, double-blind, active and placebo-controlled trial of about 300 patients over the age of 12 with acute allergic syndromes. About 100 patients will be randomly assigned to each of the 3 treatments including a non-sedating antihistamine injection as disclosed herein, a diphenhydramine injection, or a placebo injection, all via intravenous, intramuscular or subcutaneous administration. Patients will be recruited at multiple centers, from emergency departments at urban hospitals and allergy clinics throughout the country. The primary endpoints will be the reduction of pruritus severity score, pruritus duration, erythema, angioedema, wheezing, number of urticaria areas, and/or number of erythema areas, at 2-4 hours after protocol treatment. Symptom scores will be also assessed at baseline.
  • A broad definition of allergic syndromes to approximate real-life emergency department (ED) approaches will be used to assess the patients with various symptoms and signs. Patients over the age of 12 will be considered for recruitment from the ED if they have the following syndromes after an ingested food or ingested, inhaled, or injected drug, after in contact with latex or bee stings: acute urticaria (score 1 and above), acute angioedema (score 1 and above), wheezing (score 1 and above), and acute pruritic rash (score 1 and above). These manifestations should have been present for no greater than 12 hours from the time of alleged allergen exposure. Pregnant patients will be excluded. Recruited patients will be randomly assigned to treatment with either 10 mg of cetirizine injection (the test product group, i.e. product of present disclosure), diphenhydramine 50 mg injection (the comparator or active control group) or placebo injection (placebo control group)
  • Each treatment designation will be blinded based on the randomization code. The physician who is unaware of the treatment content will administer the contents by means of intravenous (or intramuscular, or subcutaneous, depending on protocol requirement) injection to the subject. Supplemental medications, such as epinephrine, corticosteroids, bronchodilators, and additional doses of antihistamine may be administered at the discretion of the study physicians as a rescue procedure. Patients may also receive supplemental oxygen and intravenous fluids at the discretion of the study physicians as a rescue procedure. Patients will have heart rate, blood pressure, physical findings, side effects, and symptoms assessed at baseline, 1 hour, 2 hours and 4 hours relative to experimental treatment. Baseline temperatures will be also recorded. Clinical recording will include the presence and extent or severity scores of urticaria and erythema, angioedema, wheezing, pruritus, number of urticaria areas, number of erythema areas, abdominal distention or tenderness, and abdominal hyperactive bowel sounds. Historical features, physical findings (including heart rates, blood pressure, and respiratory rates), and treatments will be recorded on a study-specific data input form. The extent of involvement with urticaria and erythema will be assessed by using a check-off cartoon of body areas (similar to that used to assess burn area extent) printed on the data input sheet. Symptom scores will be assessed at baseline, 1 hour, and 2, or 4 hours by using a preprinted form with none (score 0), mild (score 1), moderate (score 2), and severe (score 3) check-off categories.
  • The primary variables of interest will be resolution or reduction of urticaria, angioedema, erythema, pruritus, wheezing, number of urticaria areas, and number of erythema areas. Changes in heart rates, respiratory rates, blood pressure, and symptoms will also be examined. The final disposition of the patient will be noted (admission, discharge, or leaving against medical advice). The study will be approved by the institutional review board, and informed written consent will be obtained from all patients.
  • Statistical assessment will be using bivariate
    Figure US20120053563A1-20120301-P00001
    2 analysis and analysis of variance or covariance (ANCOVA), multivariate logistic regression. Covariates will be included in some multivariate models. Analyses will be performed by using the SAS software. Certain statistical values are expressed with 90% confidence intervals (CIs).
  • The above clinical trials may be split into two separate studies. One study will be an active controlled study comparing the invention injectable product with diphenhydramine injection. The other will be a placebo controlled study comparing the invention injectable product with a placebo.
  • In addition, pediatric studies will be conducted on patients younger than the age of 12 with similar study design and lower drug dosage.
  • Prompt treatment with antihistamines is highly recommended to alleviate the symptoms of acute allergic reactions. Antihistamines are helpful in reducing histamine-mediated vasodilation and secondary edema. Commonly used drugs such as diphenhydramine injection provide H1 blockade. Diphenhydramine reduces vasodilation in small blood vessels in the nose, eyes, and airways and provide some anticholinergic effects toward drying secretions. Diphenhydramine (1 to 2 mg/kg, up to a maximum of 50 mg, given IV or IM) is the drug of choice when treating acute allergic reactions. Concomitant administration of an H2 agonist such as ranitidine (1 mg/kg IV) or cimetidine (4 mg/kg IV) is also of value to provide antihistaminic effect.
  • Currently, the only antihistamine injection existing on the market is diphenhydramine injection, a first generation antihistamine, with known side effects of cardio toxicity (QT prolongation), severe sedation, anti-cholinergic effect, potential of drug/drug interaction, and short acting which requires 3-4 doses a day. Cardio toxicity presents a huge safety concern, and the sedation side effect causes significantly inconvenience and discomfort for patients. The sedating side effect presents a safety concern when patients have to drive home themselves after being discharged from the emergency room. The sedating side effect also interferes with neurological exams for patients who are in need such exams in the hospital. Patients with allergic reactions to opioids are treated with diphenhydramine injections. This causes a dangerous additive effect in sedation. Diphenhydramine's QT prolongation is potentially life threatening and could lead to hospital admission. Sometimes severe allergic patients come to the ER and already took a few diphenhydramine tablets. ER doctors then put the patients on injection diphenhydramine as a standard procedure. This accumulated diphenhydramine concentration could cause cardiac arrest leading to hospital admission. QT prolongation is worsened by drug/drug interaction. In ICUs, diphenhydramine injection is frequently used as a preventive measure to desensitize antibiotics (antibiotics have a high incidence for drug induced allergic shock). In ICUs, patients are normally on multiple medications, and the potential drug/drug interaction and liver enzyme P450 inhibition leading to cardiac arrest due to QT prolongation is extremely dangerous. Diphenhydramine injection is commonly used together with blood transfusion to prevent allergic reactions to blood or plasma. Clearly sedation is unwanted. Diphenhydramine injection is often used to treat anesthesia induced allergies in the operating room. It takes longer for patients to awake from the anesthesia when diphenhydramine injection is co-used.
  • Therefore there is a great advantage and unmet medical need for a non-sedating antihistamine injection with longer duration of action, and without QT prolongation.
  • In one embodiment, the present disclosure includes injectable formulations of second and third generation antihistamines, or non-sedating antihistamines, via intravenous, intramuscular, or subcutaneous administration to provide an immediate onset of action. Such second and third generation antihistamines are commercially available as oral dosage forms as shown in the following table.
  • TABLE 2
    Second and third generation antihistamines
    Currently marketed dosage form
    Second generation
    antihistamines
    cetirizine 10 mg tablet, once daily for adults over 6
    5 mg chewable, once daily for children under 6
    AUC0-24 = about 4023 ng · hr/mL for adult
    dose of 10 mg; (range: about 2500 to about
    5500 ng · hr/mL)
    AUC0-INF = about 4638 ng · hr/mL, for adult
    dose of 10 mg; (range: about 3000 to about
    6200 ng · hr/mL)
    loratidine 10 mg tablet every 12 hours for adults over 6
    5 mg chewable every 12 hours for children 2-6
    AUC0-24 = about 7.36 ng · hr/mL (fasting)
    AUC0-INF = about 7.90 ng · hr/mL (fasting)
    AUC0-24 = about 10.3 ng · hr/mL (fed)
    AUC0-INF = about 11.1 ng · hr/mL (fed)
    Third generation
    antihistamines
    fexofenadine 60 mg tablet twice daily or 180 mg tablet once
    daily for adults over 12
    30 mg tablet once daily for children 6-11
    AUC0-inf (60 mg) = about 958 ng · hr/mL
    AUC0-inf (180 mg) = about 3397 ng · hr/mL
    AUC0-INF (240 mg) = about 6571 ng · hr/mL
    levocetirizine 5 mg tablet, once daily for adults over 12
    2.5 mg tablet once daily for children 6-11
    1.25 mg (½ teaspoon oral solution) once daily
    for children 6 months to 5 years
    AUC0-24 = about 3469 ng · hr/mL; (range:
    about 1500 to about 5000 ng · hr/mL)
    AUC0-INF = about 3998 ng · hr/mL; (range:
    about 2000 to about 5500 ng · hr/mL)
    desloratadine 5 mg tablet once daily for adults over 12
    1 teaspoonful (2.5 mg in 5 mL) once daily for
    children 6 to 11
    ½ teaspoonful (1.25 mg in 2.5 mL) once daily
    for children 12 months to 5 years
    AUCss = about 56.9 ng·hr/mL
    AUC0-24 (single dose) = about 34.2 ng · hr/mL
    AUC(single dose)0-inf = about 35.6 ng/hr/mL
  • Additional non-sedating antihistamines include des-diphenhydramine, epinastine, azelastine, Acrivastine, Ebastine, carbastine, levocarbastine, Mizolastine, and Rupatadine.
  • Parenteral injectable formulations may be in unit dose form in ampoules, small volume parenteral (SVP) vials, large volume parenterals (SVP), pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, buffering, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
  • Parenteral injectable formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably at a pH of from 3 to 9.5), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • In one embodiment, the injectable compositions contain a solution of one or more non-sedating antihistamines in an aqueous solvent combined with a buffer or pH adjusting agents having a pH of 3 to 9. The composition optionally contains at least one isotonicity agent. A water-insoluble inert gas may be carefully bubbled through the aqueous solvent to remove oxygen from the medium. Optionally the compositions contain at least one preservative and/or at least one solubility enhancing agent and/or at least one stabilizing agent.
  • In one embodiment, the non-sedating H1 antihistamine is cetirizine or a salt thereof. In another embodiment, the quantity of cetirizine or salt thereof in the injection formulation is 1-100 mg per milliliter of liquid, preferably 1.5-50 mg, more preferably 2-25 mg per milliliter of liquid.
  • In another embodiment, the non-sedating H1 antihistamines is fexofenadine or a salt thereof. In yet another embodiment, the quantity of fexofenadine or salt thereof in the injection formulation is 1-200 mg per milliliter of liquid, preferably 1.5-180 mg, preferably 2-90 mg, more preferably 2.5-70 mg per milliliter of liquid.
  • In another embodiment, the injectable composition optionally comprises at least one H2 antihistamine, specifically ranitidine and cimetidine, more specifically ranitidine. Concomitant administration of an H2 agonist such as ranitidine (1 mg/kg IV) or cimetidine (4 mg/kg IV) may be of value to provide antihistaminic effect.
  • Due to the fast onset of acute allergic reactions including anaphylaxis, often patients do not have sufficient time to reach medical care facilities for treatment. In this life and death situation, it is important that patients administer medications to themselves immediately. Accordingly, there is a need in the art to develop injectable formulations and optionally self operated and ready to use auto injector products, needle or needleless, providing a rapid delivery of the injectable non-sedating antihistamine formulation.
  • An automatic injector or auto-injector is a device designed to allow a user to self-administer a pre-measured dose of a medicament composition subcutaneously or intramuscularly, usually in an emergency situation. A typical auto-injector has a housing, inside of which is a cartridge. The cartridge has one or several chambers containing medicament compositions or components thereof and is in communication with a dispensing assembly such as needle assembly. The cartridge can hold either a pre-mixed liquid medicament or a solid medicament and a liquid that are mixed prior to injection. The housing carries an actuation assembly with a stored energy source, for example, a compressed spring. Activation of the actuation assembly causes a sequence of movements, whereby the needle extends from the auto-injector into the user so that the medicament compound is then forced through the needle and into the user. After delivery of the dose of medicament into the injection site, the needle remains in an extended position or in a hidden position. If the auto-injector is of the type designed to carry plural components of the medicament composition in separate, sealed compartments, structure may be included that forces the components to mix when the actuation assembly is activated.
  • Autoinjectors for antihistamine administration do not exist. Advantages of the use of auto-injectors to dispense non-sedating (second and third generation) antihistamines for the treatment of severe allergic reactions include availability for emergency treatment, precise dosing, portability, readiness for use, rapid intramuscular or subcutaneous administration, administration through clothing and protective wear, and rapid self-administration. The advantages of this invention also include its non-cardiotoxicity (no QT prolongation), and non-sedating. Unlike the current highly sedating diphenhydramine injections, the non-sedating feature of this invention allows patients to be alert enough to drive to the hospital or emergency care facility after they self administer the non-sedating antihistamine injection via an auto injector.
  • In another embodiment, a kit comprises the automatic injector comprising a non-sedating antihistamine composition as described above, and a second automatic injector comprising a second housing comprising a second chamber for an epinephrine composition and a second dispensing assembly in communication with the second chamber.
  • In one embodiment, disclosed herein is an injectable second or third generation antihistamine (non-sedating antihistamine) formulation. Also disclosed are methods of treating an acute allergic reaction comprising administering to an individual in need thereof an effective amount of an injectable composition comprising a second or third generation antihistamine (or non-sedating antihistamine). In specific embodiments, the antihistamine is not diphenhydramine. In other embodiments, the non-sedating antihistamine is selected from cetirizine, loratadine, levocetirizine, desloratadine, and fexofenadine, des-diphenhydramine, epinastine, azelastine, Acrivastine, Ebastine, carbastine, levocarbastine, Mizolastine, and Rupatadine.
  • In one embodiment, the injectable formulation further comprises at least one H2 receptor antagonist, such as ranitidine or cimetidine. In another embodiment, the injectable formulation further comprises epinephrine. In yet another embodiment, the injectable formulation further comprises at least one steroid, such as methylprednisolone or prednisolone.
  • In one embodiment, disclosed herein are methods of treating an acute allergic reaction comprising administering to an individual in need thereof an effective amount of an injectable composition comprising a second or third generation antihistamine (or non-sedating antihistamine), wherein the injectable composition is bioequivalent to an oral formulation of the 2nd or 3rd generation antihistamine.
  • Non-sedating Dosage range of injectable
    Antihistamine Oral product formulation
    Cetirizine 10 mg tablet about 2 mg to about 10 mg
    10 mg chewable tablet
    10 mg capsule
    5 mg tablet
    5 mg/5 mL syrup
    Loratadine 10 mg tablet about 1 mg to about 10 mg
    10 mg capsule
    5 mg tablet
    5 mg chewable tablet
    0.5 mg/mL syrup
    1 mg/mL suspension
    1 mg/mL syrup
    Fexofenadine 180 mg tablet/capsule about 5 mg to about
    60 mg tablet 180 mg
    30 mg tablet
    30 mg/5 mL suspension
    Levocetirizine 5 mg tablet about 1 mg to about 5 mg
    2.5 mg tablet
    2.5 mg/5 mL syrup
    Desloratadine 5 mg tablet about 1 mg to about 5 mg
    2.5 mg/5 mL syrup
  • As used herein, the term equivalent to an oral product means that the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC0-INF and/or AUC0-t for the injectable formulation to a logarithmic transformed geometric mean of AUC0-INF and/or AUC0-t for the reference oral product are about 0.80 to about 1.25, specifically 0.80 to 1.25. “AUC” is the area under the curve of a graph of the measured concentration of an active agent (typically plasma concentration) vs. time, measured from one time point to another time point. For example AUC0-t is the area under the curve of plasma concentration versus time from time 0 to time t, the last blood draw time point. The AUC0-∞ or AUC0-INF is the calculated area under the curve of plasma concentration versus time from time 0 to time infinity by extrapolation. In one embodiment, the AUC0-INF and/or AUC0-t are given in Table 2. In another embodiment, the AUCINF and/or AUC0-t for the injectable formulation and the reference oral dosage form are given determined in a reference-controlled study.
  • In one embodiment, disclosed herein are methods of treating an acute allergic reaction including anaphylaxis comprising administering to an individual in need thereof an effective amount of an injectable composition comprising a second or third generation antihistamine (or non-sedating antihistamine), wherein the injectable composition is therapeutically equivalent to a reference diphenhydramine injectable formulation. In one embodiment, the reference diphenydramine injectable formulation is a 50 mg/mL solution, and the dose is about 12.5-150 mg dose. Diphenhydramine injection is commercially available from Pfizer as Benadryl® Injection. Many generic versions of diphenhydramine injections are also available on the market. Therapeutic equivalence can be determined in a reference-controlled study using a diphenydramine injectable formulation as the reference.
  • As used herein, therapeutically equivalent to a reference diphenydramine injectable formulation means that the test formulation has a 90% confidence interval around the difference in the reduction of at least one symptom of an acute allergic reaction including anaphylaxis of the test drug to the reference drug, for the per protocol evaluable population, within about −30.00 to about +30.00. In specific embodiments, the symptoms of anaphylaxis or an acute allergic reaction are, pruritus severity, pruritus duration, erythema, angioedema and/or wheezing reduction, and urticaria areas or erythema areas.
  • Predicted results for clinical equivalence are presented in Table 3:
  • On Treatment Difference 90% CI
    Treatment N Baseline adjusted mean from Placebo (−30.00, +30.00)
    Pruritus severity score reduction
    Cetirizine 10 mg About About 2.80 About 1.70 +0.05 About (−3.00, 8.00)
    injection 100
    Diphenhydramine About About 2.75 About 1.65
    50 mg injection 100
    Pruritus duration reduction
    Cetirizine 10 mg About About 1.00 hr −0.50 hr About (−8.50, 3.50)
    injection 100
    Diphenhydramine About About 1.50 hr
    50 mg injection 100
    Erythema Reduction
    Cetirizine 10 mg About About 2.50 About 1.0 0.00 About (−10.00,
    injection 100 10.00)
    Diphenhydramine About About 2.55 About 1.0
    50 mg injection 100
    Angioedema Reduction
    Cetirizine 10 mg About About 2.50 About 1.0 −0.25 About (−10.00,
    injection 100 8.00)
    Diphenhydramine About About 2.45 About 1.25
    50 mg injection 100
    Wheezing reduction
    Cetirizine 10 mg About About 2.45 About 1.40 +0.40 About (−0.20,
    injection 100 15.00)
    Diphenhydramine About About 2.55 About 1.00
    50 mg injection 100
    Number of urticaria areas
    Cetirizine 10 mg About About 4.2 About 1.0 −0.20 About (−10.00,
    injection 100 8.00)
    Diphenhydramine About About 4.0 About 1.20
    50 mg injection 100
    Number of erythema areas
    Cetirizine 10 mg About About 7.0 About 1.0 −1.0 About (−15.00,
    injection 100 10.00)
    Diphenhydramine About About 7.2 About 2.0
    50 mg injection 100
  • Expected results for effectiveness comparing to placebo are presented in Table 4:
  • On Treatment Difference
    Treatment N Baseline adjusted mean from Placebo P-value
    Pruritus severity score reduction
    Cetirizine 10 mg About 100 About 2.80 About 1.80 −0.70 <0.05
    injection
    Placebo injection About 100 About 2.75 About 2.50
    Pruritus duration reduction
    Cetirizine 10 mg About 100 About 1.50 hr −2.5 hr <0.05
    injection
    Placebo injection About 100 About 4.00 hr
    Erythema Reduction
    Cetirizine 10 mg About 100 About 2.50 About 1.0 −1.15 <0.05
    injection
    Placebo injection About 100 About 2.55 About 2.15
    Angioedema Reduction
    Cetirizine 10 mg About 100 About 2.50 About 1.0 −1.25 <0.05
    injection
    Placebo injection About 100 About 2.45 About 2.25
    Wheezing reduction
    Cetirizine 10 mg About 100 About 2.45 About 1.40 −0.75 <0.05
    injection
    Placebo injection About 100 About 2.55 About 2.15
    Number of urticaria areas
    Cetirizine 10 mg About 100 About 4.2 About 1.0 −2.8 <0.05
    injection
    Placebo injection About 100 About 4.0 About 3.8
    Number of erythema areas
    Cetirizine 10 mg About 100 About 6.0 About 1.0 −4.0 <0.05
    injection
    Placebo injection About 100 About 6.2 About 5.0
  • In one embodiment, disclosed herein are methods of treating an acute allergic reaction including anaphylaxis comprising administering to an individual in need thereof an effective amount of an injectable composition comprising a second or third generation antihistamine, the non-sedating antihistamine, wherein the injectable composition is therapeutically effective compared to placebo. As used herein, a placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness. A placebo-controlled study is a method of investigation of drugs in which an inactive substance (the placebo) is given to one group of participants, while the drug being tested is given to another group. The results obtained in the two groups are then compared to see if the investigational treatment is more effective in treating the condition.
  • As used herein, therapeutically effective compared to placebo means that the treatment of this invention is statistically superior (p<0.05) to a placebo in the reduction of at least one symptom of anaphylaxis or an acute allergic reaction, wherein the symptom is pruritus severity, pruritus duration, erythema, angioedema, urticaria areas, erythema areas, and/or wheezing.
  • The methods described herein optionally further comprise administering a second active agent as well as the second or third generation antihistamine. In one embodiment, the second active agent is an H2 receptor antagonist, such as ranitidine or cimetidine. In another embodiment, the second active agent is epinephrine. In yet another embodiment, the second active agent comprises at least one steroid, such as methylprednisolone or prednisolone. In one embodiment, the methods disclosed herein further comprise administering a second active agent comprising ranitidine, cimetidine, epinephrine, methylprednisolone, prednisolone, or a combination thereof.
  • The terms “a” and “an” do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term “or” means “and/or.” The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”). Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. The endpoints of all ranges directed to the same component or property are inclusive and independently combinable.
  • The term “non-sedating antihistamines” represent the 2nd and/or 3rd generation antihistamines that are truly non-sedating and that are less-sedating than diphenhydramine.
  • The term “antihistamine” can also be expressed as “antagonist of the H1 receptor” or “H1 antihistamine”.
  • The term “Therapeutic equivalence” can also be expressed as “clinical equivalence”, “clinically bioequivalent”, or “clinical endpoint bioequivalence”.
  • The term “equivalent” can also be expressed as “bioequivalent”.
  • “Acute allergic reaction” means an allergic condition of the immediate type, severe allergies/anaphylaxis, or severe allergic reaction such as allergic reactions to blood or plasma, to food, to medications, or to other allergy inducing materials.
  • Embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments would become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims (8)

1. A method of treating acute urticaria or angioedema associated with an acute allergic reaction including anaphylaxis in an individual in need thereof, comprising
self-administering from an automatic injector a pre-measured dose of a non-sedating antihistamine composition subcutaneously or intramuscularly,
wherein the non-sedating antihistamine composition comprises a non-sedating antihistamine and a pH adjusting agent and has a pH of 3 to 9, wherein the non-sedating antihistamine comprises cetirizine or a salt thereof,
wherein the automatic injector comprises a housing comprising a chamber for the non-sedating antihistamine composition and a dispensing assembly in communication with the chamber.
2. The method of claim 1, wherein the non-sedating antihistamine composition further comprises ranitidine, cimetidine, epinephrine, methylprednisolone, prednisolone, or a combination thereof.
3. The method of claim 1, further comprising self-administering from a second automatic injector an epinephrine composition, wherein the second automatic injector comprises a second housing comprising a second chamber for the epinephrine composition and a second dispensing assembly in communication with the second chamber.
4. The method of claim 1, wherein treating is in an emergency situation.
5. The method of claim 1, wherein self-administering the non-sedating antihistamine from the automatic injector is non-cardiotoxic and non-sedating.
6. An automatic injector for self-administration of a pre-measured dose of a non-sedating antihistamine composition subcutaneously or intramuscularly, comprising
a housing comprising a chamber for the non-sedating antihistamine composition and a dispensing assembly in communication with the chamber,
wherein the non-sedating antihistamine composition comprises a non-sedating antihistamine and a pH adjusting agent and has a pH of 3 to 9, wherein the non-sedating antihistamine comprises cetirizine or a salt thereof.
7. The automatic injector of claim 6, wherein the non-sedating antihistamine composition further comprises ranitidine, cimetidine, epinephrine, methylprednisolone, prednisolone, or a combination thereof.
8. A kit comprising the automatic injector comprising a non-sedating antihistamine composition of claim 6, and a second automatic injector comprising a second housing comprising a second chamber for an epinephrine composition and a second dispensing assembly in communication with the second chamber.
US13/291,514 2009-07-03 2011-11-08 Non-sedating antihistamine injection formulations and methods of use thereof Abandoned US20120053563A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/291,514 US20120053563A1 (en) 2009-07-03 2011-11-08 Non-sedating antihistamine injection formulations and methods of use thereof
US13/940,747 US9161902B2 (en) 2009-07-03 2013-07-12 Non-sedating antihistamine injection formulations and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22295109P 2009-07-03 2009-07-03
US24844109P 2009-10-03 2009-10-03
US12/704,089 US8263581B2 (en) 2009-07-03 2010-02-11 Non-sedating antihistamine injection formulations and methods of use thereof
US13/291,514 US20120053563A1 (en) 2009-07-03 2011-11-08 Non-sedating antihistamine injection formulations and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/704,089 Division US8263581B2 (en) 2009-07-03 2010-02-11 Non-sedating antihistamine injection formulations and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/940,747 Division US9161902B2 (en) 2009-07-03 2013-07-12 Non-sedating antihistamine injection formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
US20120053563A1 true US20120053563A1 (en) 2012-03-01

Family

ID=43411481

Family Applications (6)

Application Number Title Priority Date Filing Date
US12/704,089 Active 2030-02-28 US8263581B2 (en) 2009-07-03 2010-02-11 Non-sedating antihistamine injection formulations and methods of use thereof
US12/829,857 Active 2030-04-16 US8314083B2 (en) 2009-07-03 2010-07-02 Non-sedating antihistamine injection formulations and methods of use thereof
US13/291,514 Abandoned US20120053563A1 (en) 2009-07-03 2011-11-08 Non-sedating antihistamine injection formulations and methods of use thereof
US13/559,954 Active 2030-07-29 US9119771B2 (en) 2009-07-03 2012-07-27 Non-sedating antihistamine injection formulations and methods of use thereof
US13/644,290 Active 2030-04-08 US9180090B2 (en) 2009-07-03 2012-10-04 Non-sedating antihistamine injection formulations and methods of use thereof
US13/940,747 Active 2030-05-26 US9161902B2 (en) 2009-07-03 2013-07-12 Non-sedating antihistamine injection formulations and methods of use thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/704,089 Active 2030-02-28 US8263581B2 (en) 2009-07-03 2010-02-11 Non-sedating antihistamine injection formulations and methods of use thereof
US12/829,857 Active 2030-04-16 US8314083B2 (en) 2009-07-03 2010-07-02 Non-sedating antihistamine injection formulations and methods of use thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/559,954 Active 2030-07-29 US9119771B2 (en) 2009-07-03 2012-07-27 Non-sedating antihistamine injection formulations and methods of use thereof
US13/644,290 Active 2030-04-08 US9180090B2 (en) 2009-07-03 2012-10-04 Non-sedating antihistamine injection formulations and methods of use thereof
US13/940,747 Active 2030-05-26 US9161902B2 (en) 2009-07-03 2013-07-12 Non-sedating antihistamine injection formulations and methods of use thereof

Country Status (6)

Country Link
US (6) US8263581B2 (en)
EP (1) EP2477634B1 (en)
AU (1) AU2010266103B2 (en)
CA (1) CA2803987C (en)
ES (1) ES2616703T3 (en)
WO (1) WO2011003074A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110004164A1 (en) * 2009-07-03 2011-01-06 Jie Du Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8945063B2 (en) 2009-03-20 2015-02-03 Antares Pharma, Inc. Hazardous agent injection system
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
US9180259B2 (en) 2005-01-24 2015-11-10 Antares Pharma, Inc. Prefilled syringe jet injector
US20150352102A1 (en) * 2013-03-13 2015-12-10 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US9333309B2 (en) 2002-02-11 2016-05-10 Antares Pharma, Inc. Intradermal injector
US9364611B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US9393367B2 (en) 2013-03-12 2016-07-19 Antares Pharma, Inc. Prefilled syringes and kits thereof
US9446195B2 (en) 2011-07-15 2016-09-20 Antares Pharma, Inc. Injection device with cammed ram assembly
US9486583B2 (en) 2012-03-06 2016-11-08 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US9561333B2 (en) 2008-08-05 2017-02-07 Antares Pharma, Inc. Multiple dosage injector
US9707354B2 (en) 2013-03-11 2017-07-18 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US9744302B2 (en) 2013-02-11 2017-08-29 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US9808582B2 (en) 2006-05-03 2017-11-07 Antares Pharma, Inc. Two-stage reconstituting injector
US9867949B2 (en) 2008-03-10 2018-01-16 Antares Pharma, Inc. Injector safety device
US9925183B2 (en) 2014-09-15 2018-03-27 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US9937166B2 (en) 2013-03-13 2018-04-10 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
US10201537B2 (en) 2013-03-13 2019-02-12 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US10206919B2 (en) 2013-03-13 2019-02-19 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US10537568B2 (en) 2010-06-16 2020-01-21 IRR, Inc. Use of levocetirizine and montelukast to ameliorate inflammation following radiation exposure

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
CN107961214B (en) * 2016-10-18 2021-08-24 北京科信必成医药科技发展有限公司 Cetirizine injection
CN107961215B (en) * 2016-10-20 2021-08-24 北京科信必成医药科技发展有限公司 Levocetirizine injection
ES2953520T3 (en) 2016-12-23 2023-11-14 Maregade Rx Llc Low dose product and method for the treatment of diarrhea
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
US11253513B2 (en) 2019-10-07 2022-02-22 Jdp Therapeutics Llc Dosing regimen for injectable cetirizine
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031893A (en) * 1976-05-14 1977-06-28 Survival Technology, Inc. Hypodermic injection device having means for varying the medicament capacity thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117141A (en) 1977-02-18 1978-09-26 Dov Michaeli Method of inhibiting flea-bite allergy
FI75816C (en) 1981-02-06 1988-08-08 Ucb Sa Process for the preparation of therapeutically active 2- [4- (diphenylmethyl) -1-piperazinyl] -acetic acid or its amide
US4434237A (en) 1982-03-31 1984-02-28 Dinarello Charles A Human leukocytic pyrogen test for the detection of exogenous fever-producing substances
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5093360A (en) 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5276044A (en) 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
CA2145413A1 (en) * 1992-09-24 1994-03-31 Nancy M. Gray Methods and compositions for treating allergic disorders using optically pure (+) cetirizine
EP0950412A3 (en) 1992-09-24 2001-05-16 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
KR100329887B1 (en) 1992-11-02 2002-11-02 시오노기세이야쿠가부시키가이샤 (E) -Method for preparing alkoxyimino- and hydroxyimino-acetamide compounds and intermediates for preparation thereof
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US20020048596A1 (en) 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
FR2732221B1 (en) 1995-03-28 1997-04-25 Oreal USE OF A CGRP ANTAGONIST TO TREAT CUTANEOUS REDNESS OF NEUROGENIC ORIGIN AND COMPOSITION OBTAINED
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
IL127691A0 (en) 1996-06-28 1999-10-28 Oxigene Inc Useful formulations of acid addition salt drugs
JP2002514194A (en) 1996-11-19 2002-05-14 ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド Topical use of IL-1RA in rejection of corneal transplantation or eye disease
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
IN188720B (en) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
US6660301B1 (en) 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US20050158408A1 (en) 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
IT1303671B1 (en) 1998-07-28 2001-02-23 Nicox Sa SALTS OF NITRIC ACID WITH ACTIVE DRUGS IN THE TREATMENT OF DISEASES OF THE RESPIRATORY SYSTEM
US6432961B1 (en) 1998-08-18 2002-08-13 Ucb S.A. Method for preventing the onset of asthma
TW581675B (en) 1998-08-18 2004-04-01 Ucb Sa A pharmaceutical composition for use in preventing the onset of asthma in a patient
BR9804993A (en) 1998-11-10 2000-06-06 Panacea Biotec Ltd Antiallergic and anti-inflammatory composition
CH693625A5 (en) 1999-02-18 2003-11-28 Inpharma Sa Pharmaceutical compositions containing compounds of promoter activity of absorption of active ingredients.
US20040185145A1 (en) 1999-07-22 2004-09-23 Ehrman Richard A. Food product and related method
NZ518052A (en) 1999-09-28 2005-04-29 Panacea Biotec Ltd Controlled release compositions comprising nimesulide (4-nitro-2-phenoxymethanesulfonanilide) for a once-a-day oral dosage to treat diseases such as arthritis
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6458384B2 (en) 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
US7338657B2 (en) 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6258814B1 (en) 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
WO2002047689A2 (en) 2000-12-15 2002-06-20 Ucb, S.A. Use of cetirizine or efletirizine for preventing urticaria
JP4074427B2 (en) 2000-12-18 2008-04-09 株式会社栃木臨床病理研究所 Preventive or therapeutic agent for endometriosis
PT1353668E (en) 2001-01-25 2008-06-30 Bristol Myers Squibb Co Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030144336A1 (en) 2001-08-27 2003-07-31 Pfizer Inc. Method of selecting nonsedating H1-antagonists
US20030134811A1 (en) 2001-10-09 2003-07-17 John Jackson Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
CA2471948A1 (en) 2002-01-03 2003-07-17 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
JP2003212773A (en) 2002-01-04 2003-07-30 Oramon Arzneimittel Gmbh Topical medicine composition of cetirizine and loratadine
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
CA2487712A1 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
ATE386526T1 (en) 2002-07-02 2008-03-15 Ucb Farchim Sa DIARYLMETHYLPIPERAZINES AS PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST VIRAL MYOCARDITIS
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
AU2003287526A1 (en) 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
CA2506965A1 (en) 2002-12-03 2004-06-17 Ucb Farchim S.A. Use of levocetirizine for the treatment of persistent allergic rhinitis
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
SE0300831D0 (en) 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use therof
ZA200507877B (en) 2003-03-31 2007-01-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
KR101208291B1 (en) 2003-04-04 2012-12-05 노파르티스 아게 High concentration antibody and protein formulations
CA2522007A1 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US20050032173A1 (en) 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
US20050031713A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients
US20070020196A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20050192290A1 (en) 2004-01-13 2005-09-01 Isaac Melamed Treatment of behavioral disorders
US20050208134A1 (en) 2004-02-25 2005-09-22 Shlomo Magdassi Biocompatible polymeric beads and use thereof
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US20050282879A1 (en) 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
DE602004022523D1 (en) 2004-07-02 2009-09-24 Novagali Pharma Sa Use of emulsions for intra- and periocular injection
US20070213660A1 (en) 2004-10-29 2007-09-13 Mark Richards Fibrin sealant delivery device including pressure monitoring, and method and kits thereof
US8357147B2 (en) 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
US20090054994A1 (en) 2007-08-21 2009-02-26 James Rogan Methods and kits for prophylactically reinforcing degenerated spinal discs and facet joints near a surgically treated spinal section
US20070286881A1 (en) 2005-07-14 2007-12-13 Brian Burkinshsw Method, composition and kit for treating degenerated disc disease and discogenic pain
US8403923B2 (en) 2004-10-29 2013-03-26 Spinal Restoration, Inc. Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US8419722B2 (en) 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
US8206448B2 (en) 2004-10-29 2012-06-26 Spinal Restoration, Inc. Injection of fibrin sealant using reconstituted components in spinal applications
US9132116B2 (en) 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
WO2006037047A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US20060079846A1 (en) 2004-10-08 2006-04-13 Alton Williams Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such
JP2008517938A (en) * 2004-10-25 2008-05-29 シェーリング コーポレイション M1 receptor antagonist and / or M3 receptor antagonist in combination with other active agents to treat respiratory disorders
CN101119713A (en) 2004-11-24 2008-02-06 阿尔高克斯制药公司 Capsaicinoid gel formulation and uses thereof
US20060211754A1 (en) 2005-03-16 2006-09-21 Yu Ruey J Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof
US20060216363A1 (en) 2005-03-28 2006-09-28 Liu Su Y Novel herbal composition
EP2397034A1 (en) 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
JP5155883B2 (en) 2006-01-25 2013-03-06 ターロ ファーマシューティカルズ ノース アメリカ インコーポレイテッド Antihistamine composition and use thereof
TW200744568A (en) * 2006-02-28 2007-12-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens
TW200744697A (en) 2006-02-28 2007-12-16 Verus Pharmaceuticals Inc Shock absorber for an automatic injector
CA2645080A1 (en) 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
JP2010502723A (en) 2006-09-11 2010-01-28 ボーシュ アンド ローム インコーポレイティド Compositions and methods for treating, controlling, reducing, ameliorating or preventing allergies
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
FR2906140B1 (en) 2006-09-22 2008-12-05 Philippe Perovitch GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS
US20080145405A1 (en) 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
US8476243B2 (en) 2006-12-29 2013-07-02 Transderm, Inc. Methods and compositions for treating keratin hyperproliferative disorders
CN103554263B (en) 2007-03-22 2016-09-28 健泰科生物技术公司 Apoptotic anti-IgE antibodies in conjunction with the IgE that film combines
US20080294261A1 (en) 2007-05-24 2008-11-27 Kevin Pauza Method for treating herniated discs
CA2695127A1 (en) 2007-07-30 2009-02-05 Immuneregen Biosciences, Inc. Methods of treating blood cell depletion
GB0719518D0 (en) 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
EP2067469A1 (en) 2007-11-06 2009-06-10 Teva Pharmaceutical Industries Ltd. Chewable formulations
US7875001B2 (en) 2008-02-25 2011-01-25 Americo Michael Minotti Multi medication nasal spray device and method
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ATE532505T1 (en) 2008-04-18 2011-11-15 Novaliq Gmbh INHALATIVE AND INSTILLATIVE USE OF SEMIFLUORINATED ALKANES AS ACTIVE CARRIERS IN THE INTRAPULMONAL AREA
US7883488B2 (en) 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
US7883487B2 (en) 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
US8080550B2 (en) 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031893A (en) * 1976-05-14 1977-06-28 Survival Technology, Inc. Hypodermic injection device having means for varying the medicament capacity thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dux et al (Brit J Pharmacol 137:874-880, 2002) *

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737670B2 (en) 2002-02-11 2017-08-22 Antares Pharma, Inc. Intradermal injector
US9333309B2 (en) 2002-02-11 2016-05-10 Antares Pharma, Inc. Intradermal injector
US9180259B2 (en) 2005-01-24 2015-11-10 Antares Pharma, Inc. Prefilled syringe jet injector
US10478560B2 (en) 2005-01-24 2019-11-19 Antares Pharma, Inc. Prefilled syringe injector
US11446441B2 (en) 2005-01-24 2022-09-20 Antares Pharma, Inc. Prefilled syringe injector
US9629959B2 (en) 2005-01-24 2017-04-25 Antares Pharma, Inc. Prefilled syringe jet injector
US9808582B2 (en) 2006-05-03 2017-11-07 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
US10543316B2 (en) 2006-05-03 2020-01-28 Antares Pharma, Inc. Injector with adjustable dosing
US10688250B2 (en) 2006-05-03 2020-06-23 Antares Pharma, Inc. Two-stage reconstituting injector
US11547808B2 (en) 2006-05-03 2023-01-10 Antares Pharma, Inc. Two-stage reconstituting injector
US11471600B2 (en) 2006-05-03 2022-10-18 Antares Pharma, Inc. Injector with adjustable dosing
US11684723B2 (en) 2008-03-10 2023-06-27 Antares Pharma, Inc. Injector safety device
US10709844B2 (en) 2008-03-10 2020-07-14 Antares Pharma, Inc. Injector safety device
US9867949B2 (en) 2008-03-10 2018-01-16 Antares Pharma, Inc. Injector safety device
US9561333B2 (en) 2008-08-05 2017-02-07 Antares Pharma, Inc. Multiple dosage injector
US10300212B2 (en) 2008-08-05 2019-05-28 Antares Pharma, Inc. Multiple dosage injector
US11058824B2 (en) 2008-08-05 2021-07-13 Antares Pharma, Inc. Multiple dosage injector
US11497753B2 (en) 2009-03-20 2022-11-15 Antares Pharma, Inc. Hazardous agent injection system
US9750881B2 (en) 2009-03-20 2017-09-05 Antares Pharma, Inc. Hazardous agent injection system
US10555954B2 (en) 2009-03-20 2020-02-11 Antares Pharma, Inc. Hazardous agent injection system
US8945063B2 (en) 2009-03-20 2015-02-03 Antares Pharma, Inc. Hazardous agent injection system
US9161902B2 (en) 2009-07-03 2015-10-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US20110004164A1 (en) * 2009-07-03 2011-01-06 Jie Du Non-sedating antihistamine injection formulations and methods of use thereof
US8314083B2 (en) 2009-07-03 2012-11-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9119771B2 (en) 2009-07-03 2015-09-01 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9180090B2 (en) 2009-07-03 2015-11-10 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US10537568B2 (en) 2010-06-16 2020-01-21 IRR, Inc. Use of levocetirizine and montelukast to ameliorate inflammation following radiation exposure
US11185642B2 (en) 2011-07-15 2021-11-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9446195B2 (en) 2011-07-15 2016-09-20 Antares Pharma, Inc. Injection device with cammed ram assembly
US10568809B2 (en) 2011-07-15 2020-02-25 Ferring B.V. Liquid-transfer adapter beveled spike
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US10279131B2 (en) 2011-07-15 2019-05-07 Antares Pharma, Inc. Injection device with cammed RAM assembly
US9486583B2 (en) 2012-03-06 2016-11-08 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US11602597B2 (en) 2012-03-06 2023-03-14 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US10478559B2 (en) 2012-03-06 2019-11-19 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US11771646B2 (en) 2012-04-06 2023-10-03 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
US10821072B2 (en) 2012-04-06 2020-11-03 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
US10357609B2 (en) 2012-05-07 2019-07-23 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US11446440B2 (en) 2012-05-07 2022-09-20 Antares Pharma, Inc. Needle assisted injection device having reduced trigger force
US10905827B2 (en) 2012-05-07 2021-02-02 Antares Pharma, Inc. Injection device with cammed ram assembly
US9364611B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US10881798B2 (en) 2013-02-11 2021-01-05 Antares Pharma, Inc. Needle assisted injection device having reduced trigger force
US9744302B2 (en) 2013-02-11 2017-08-29 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US11813435B2 (en) 2013-02-11 2023-11-14 Antares Pharma, Inc. Needle assisted injection device having reduced trigger force
US10610649B2 (en) 2013-03-11 2020-04-07 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US11628260B2 (en) 2013-03-11 2023-04-18 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US9707354B2 (en) 2013-03-11 2017-07-18 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US10675400B2 (en) 2013-03-12 2020-06-09 Antares Pharma, Inc. Prefilled syringes and kits thereof
US9393367B2 (en) 2013-03-12 2016-07-19 Antares Pharma, Inc. Prefilled syringes and kits thereof
US11344545B2 (en) 2013-03-13 2022-05-31 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US11103500B2 (en) 2013-03-13 2021-08-31 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9937166B2 (en) 2013-03-13 2018-04-10 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US20200101067A1 (en) * 2013-03-13 2020-04-02 IRR, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
US20150352102A1 (en) * 2013-03-13 2015-12-10 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
US10201537B2 (en) 2013-03-13 2019-02-12 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US10206919B2 (en) 2013-03-13 2019-02-19 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US9925183B2 (en) 2014-09-15 2018-03-27 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US10792281B2 (en) 2014-09-15 2020-10-06 IRR, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US11590125B2 (en) 2014-09-15 2023-02-28 IRR, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US10195193B2 (en) 2014-09-15 2019-02-05 IRR, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions

Also Published As

Publication number Publication date
EP2477634A1 (en) 2012-07-25
US20110003781A1 (en) 2011-01-06
ES2616703T3 (en) 2017-06-14
US9119771B2 (en) 2015-09-01
EP2477634B1 (en) 2016-11-30
US8314083B2 (en) 2012-11-20
WO2011003074A1 (en) 2011-01-06
US8263581B2 (en) 2012-09-11
AU2010266103B2 (en) 2016-04-14
US9180090B2 (en) 2015-11-10
US20130296829A1 (en) 2013-11-07
AU2010266103A1 (en) 2012-02-16
CA2803987A1 (en) 2011-01-06
US20110004164A1 (en) 2011-01-06
EP2477634A4 (en) 2013-01-02
CA2803987C (en) 2017-11-28
US20120289489A1 (en) 2012-11-15
US20130030010A1 (en) 2013-01-31
US9161902B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
US9161902B2 (en) Non-sedating antihistamine injection formulations and methods of use thereof
Farnam et al. Nonallergic drug hypersensitivity reactions
JPH10505864A (en) Compositions useful in the manufacture of a medicament for the treatment of various persistent diseases
CN109562281A (en) The prodrug of phenols TRPV1 agonist is combined with local anesthetic and vasoconstrictor for improving local anaesthesia
US10660872B2 (en) Methods for treatment of cognitive decline
US8513259B2 (en) Non-sedating antihistamine injection formulations and methods of use thereof
WO2014164281A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
Rizvi et al. Chlorpheniramine, an old drug with new potential clinical applications: a comprehensive review of the literature
Pryor et al. New therapies and delivery mechanisms for treatment of erectile dysfunction
US20240100043A1 (en) Dosing regimen for injectable cetirizine
Kara et al. Comparison of Intravenous Lipid Emulsion, Bicarbonate, and Glucagon Treatments in a Rabbit Model of Clomipramine Toxicity.
CN114392269A (en) Antiallergic injection composition and preparation method and application thereof
WO2023049205A1 (en) Compositions and methods for treating and preventing interstitial cystitis
Church et al. Principles of pharmacotherapy
Yoo et al. Osmotically Balanced, Large Unilamellar Liposomes for Sustained Bupivacaine Release: From the Development of Liposomes to Their in Vivo Application
Zhu et al. Effect of chloroprocaine combined with morphine on analgesia, adverse reactions and dynamic changes in inflammation in patients receiving TURP
US20060099172A1 (en) Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza
CN110179829A (en) The combination of Gabapentin, Neurotropin and Sinomenine is preparing the application in the drug for treating PHN
Del Rosso Cutaneous rosacea: a thorough overview of pathogenesis, clinical presentations, and current recommendations on management
Gottschalk et al. Allergy and Anaphylaxis
Pondok A Woman with Headache and Chest Pain

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION